Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2026
Reporting Period: Single event date (June 9, 2026)
The filing discloses a strategic licensing agreement entered into by the Company with WestGene Biopharma Co. to advance the development of novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies specifically targeting autoimmune diseases.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a material event and does not contain periodic financial statements.
Material Changes
- Strategic Partnership: Execution of a licensing agreement with WestGene Biopharma Co.
- Therapeutic Focus: Expansion into in vivo CAR-T therapies for autoimmune diseases.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the agreement. The filing explicitly states that the information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Forward-Looking Statements: The Company undertakes no obligation to update, supplement, or amend the materials attached as Exhibit 99.1, except as required by law.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 for specific financial terms of the licensing agreement (e.g., upfront payments, milestones, royalties).
- Verify the scope of rights granted to WestGene Biopharma Co. regarding the in vivo CAR-T platform.
- Confirm the impact of this agreement on the Company's cash runway and future capital requirements, as no financial data is included in this specific filing.